Development of the tumor vascular bed in response to hypoxia‐induced VEGF‐A differs from that in tumors with constitutive VEGF‐A expression
Open Access
- 27 June 2006
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 119 (9) , 2054-2062
- https://doi.org/10.1002/ijc.22072
Abstract
Tumors arise initially as avascular masses in which central hypoxia induces expression of vascular endothelial growth factor‐A (VEGF‐A) and subsequently tumor vascularization. However, VEGF‐A can also be constitutively expressed as a result of genetic events. VEGF‐A is alternatively spliced to yield at least 6 different isoforms. Of these, VEGF‐A121 is freely diffusible whereas basically charged domains in the larger isoforms confer affinity for cell surface or extracellular matrix components. We previously reported that in a mouse brain metastasis model of human melanoma, VEGF‐A121 induced a qualitatively different tumor vascular phenotype than VEGF‐A165 and VEGF‐A189: in contrast to the latter ones, and VEGF‐A121 did not induce a neovascular bed but rather led to leakage and dilatation of preexistent brain vessels. Here, we correlate vascular phenotypes with spatial VEGF‐A expression profiles in clinical brain tumors (low grade gliomas; n = 6, melanoma metastases; n = 4, adenocarcinoma metastases; n = 4, glioblastoma multiforme; n = 3, sarcoma metastasis; n = 1, renal cell carcinoma metastasis; n = 1). We show that tumors that constitutively express VEGF‐A present with different vascular beds than tumors in which VEGF‐A is expressed as a response to central hypoxia. This phenotypic difference is consistent with a model where in tumors with constitutive VEGF‐A expression, all isoforms exert their effects on vasculature, resulting in a classical angiogenic phenotype. In tumors where only central parts express hypoxia‐induced VEGF‐A, the larger angiogenic isoforms are retained by extracellular matrix, leaving only freely diffusible VEGF‐A121 to exert its dilatation effects on distant vessels.Keywords
Funding Information
- Dutch Cancer Society (5.91898)
- Radboud University Nijmegen Medical Centre
This publication has 36 references indexed in Scilit:
- Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumorsThe Journal of cell biology, 2005
- Extracellular matrix‐bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligationThe FASEB Journal, 2003
- GLUT‐1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole bindingInternational Journal of Cancer, 2003
- VEGF165 mediates formation of complexes containing VEGFR‐2 and neuropilin‐1 that enhance VEGF165‐receptor bindingJournal of Cellular Biochemistry, 2002
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Role of Fibrin Matrix in AngiogenesisAnnals of the New York Academy of Sciences, 2001
- Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cellsOncogene, 2000
- von Hippel-Lindau Syndrome: Target for Anti-Vascular Endothelial Growth Factor (VEGF) Receptor TherapyThe Oncologist, 2000
- VEGF145, a Secreted Vascular Endothelial Growth Factor Isoform That Binds to Extracellular MatrixJournal of Biological Chemistry, 1997
- The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic PotencyJournal of Biological Chemistry, 1996